TipRanks
Advertisement
Advertisement

CTOR Stock Latest News

Citius Oncology Shareholders Approve Directors and Auditor
Company AnnouncementsCitius Oncology Shareholders Approve Directors and Auditor
3d ago
8K
CTOR
Is CTOR a Buy, Before Earnings?
PremiumPre-Earnings
Is CTOR a Buy, Before Earnings?
2M ago
CTOR
Citius Oncology adds independent director to expanded board
PremiumCompany Announcements
Citius Oncology adds independent director to expanded board
2M ago
8K
CTOR
Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained
2M ago
CTOR
Citius Oncology reports strong LYMPHIR commercial momentum
PremiumCompany Announcements
Citius Oncology reports strong LYMPHIR commercial momentum
2M ago
8K
CTOR
Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3
PremiumThe FlyCitius Oncology reports availability of Lymphir in institutions grew 78% in Q3
2M ago
CTOR
CTXR
Citius Oncology provides update on commercial launch of Lymphir
Premium
The Fly
Citius Oncology provides update on commercial launch of Lymphir
2M ago
CTOR
CTXR
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
Premium
Company Announcements
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
4M ago
8K
CTOR
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
PremiumThe Fly
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
4M ago
CTOR
CTXR
Citius Oncology registers to sell 32.93M shares of common stock for holders
PremiumThe Fly
Citius Oncology registers to sell 32.93M shares of common stock for holders
4M ago
CTOR
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
4M ago
CTOR
Citius Oncology Secures New Financing to Support LYMPHIR
PremiumCompany Announcements
Citius Oncology Secures New Financing to Support LYMPHIR
5M ago
8K
CTOR
Citius Oncology Begins First European Expansion of LYMPHIR
PremiumCompany AnnouncementsCitius Oncology Begins First European Expansion of LYMPHIR
5M ago
8K
CTOR
Citius Oncology announces initial shipment of LYMPHIR to Europe
Premium
The Fly
Citius Oncology announces initial shipment of LYMPHIR to Europe
5M ago
CTOR
CTXR
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
Premium
Company Announcements
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
5M ago
8K
CTOR
Citius Oncology highlights early LYMPHIR commercial traction, expansion
PremiumCompany Announcements
Citius Oncology highlights early LYMPHIR commercial traction, expansion
6M ago
8K
CTOR
Citius Oncology provides commercial update on lymphir launch
PremiumThe Fly
Citius Oncology provides commercial update on lymphir launch
6M ago
CTOR
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
PremiumCompany Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
7M ago
8K
CTOR
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
PremiumThe Fly
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
7M ago
CTOR
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
PremiumCompany AnnouncementsCitius Oncology Announces Positive Phase 1 LYMPHIR Data
7M ago
8K
CTOR
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
Premium
The Fly
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
7M ago
CTOR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
Premium
The Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
8M ago
CTOR
CTXR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >